TrevogrumabCheck methods and identity
What the COURAGE MRI substudy measured in the thigh
3 numbered sourcesSource years 2024–2026
Peptides are short amino-acid chains linked by peptide bonds. Some bind particular proteins, and larger proteins can recognize targets through a similar principle. Trevogrumab is an investigational monoclonal antibody, a large protein engineered to block myostatin, also called GDF8. In 2026, the COURAGE trial sponsor reported an MRI substudy that asked whether adding this antibody to semaglutide changed thigh muscle volume. [1, 2, 3]
The trial’s body composition measurements included two types of scans. Dual-energy X-ray absorptiometry, or DXA, can estimate lean mass across the body. MRI can provide a more direct view of the size of particular tissues in a chosen region. In this substudy, investigators examined fat-free muscle volume in the thigh. That let them ask a question about a specific group of muscles alongside the whole-body lean mass comparison. [1]
The sponsor reported that the groups assigned to the antibody with semaglutide lost less thigh muscle volume than the group receiving semaglutide alone among participants with evaluable MRI data. The sponsor described the differences as representing roughly 70% preservation of the amount otherwise lost in the comparison group. This is a relative comparison of losses. It does not indicate that the groups gained 70% in muscle volume or that all participants had the same response. [1]
The finding was presented in a sponsor report about a predefined substudy. An MRI volume measurement does not measure how much force a person can generate or how easily they can walk or climb stairs. The result is specific to the trial’s studied arms and participants with scans that could be analyzed. Trevogrumab remains investigational. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). (opens in a new tab)
clinicaltrials.gov↩ Back to text
